What were the key takeaways from Bioceres Crop's earnings call?

What guidance did Bioceres Crop's management provide for the next earnings period?

What does Bioceres Crop do and what are its main business segments?

What were the key takeaways from Bioceres Crop’s earnings call?

What is Bioceres Crop's gross profit margin?

What is the revenue and EPS growth rate for Bioceres Crop year over year?

Did Bioceres Crop beat or miss consensus estimates last quarter?

What is Bioceres Crop's latest dividend and current dividend yield?

- **Margin transformation success**: 650bps gross margin expansion to 47% despite 17% revenue decline, driven by high-margin seed treatments and cost cuts.
- **Profitability rebound**: EBITDA up 61% to $13.6M, with $5.9M SG&A savings and working capital efficiency improvements.
- **Strategic focus on profitability**: Exiting low-margin businesses, reducing debt to 6.8x EBITDA, and maintaining liquidity amid Argentina macro challenges.
- **Key risks**: Argentina's slow recovery, delayed Europe biostimulant sales, and ongoing debt disputes.

**【CEO Summary Section】**
- Q1 2026 revenue declined 17% YoY to $77.5 million, driven by strategic reduction of low-margin, working capital-intensive sales.
- Gross margin expanded 650 basis points to 47%, with significant improvements in Crop Protection (44% vs. 39% prior) and Seed & Integrated Products (60% vs. 36% prior).
- Adjusted EBITDA rose 61% YoY to $13.6 million, supported by $5.9 million SG&A cost reduction and gross profit resilience.
- Working capital improved to 4 months of annual sales (target), despite seasonal demand.
- Debt reduced to $242.5 million, with net debt/EBITDA ratio improving to 6.8x.

**【Financial Highlights】**
- Crop Protection revenue down 16% YoY ($39.9M) due to Argentina's slow recovery and U.S./Brazil timing delays.
- Seed & Integrated Products revenue fell 37% YoY ($12.6M) as HB4 downstream program unwinds, but gross profit rose 33% due to higher-margin seed treatment packs.
- Crop Nutrition revenue stable at $25.1 million, with Argentina fertilizer volumes offsetting Paraguay/Uruaguay delays.
- Gross profit decline limited to 3% YoY ($36.2M) vs. 17% revenue drop, reflecting margin expansion.

**【Q&A Key Highlights】**
- Argentina's agricultural boom (beef, milk) may create indirect demand for U.S. farmers, but company focuses on serving local markets with U.S.-manufactured bioprotection products.
- Corteva Europe biostimulant sales lagged expectations, with limited progress in Q1 and hopes for later-year recovery.
- Company disputes claims by noteholders but remains current on all debt obligations, prioritizing financial flexibility.


Bioceres Crop Solutions Corp. (BIOX) Q1 2026 Earnings Call Transcript

- **Revenue Decline**: FY2025 revenue $335.3M (-28% YoY), driven by Argentina demand weakness and HB4 wind-down.
- **Strategic Shifts**: Transition to royalty-based HB4 model and focus on high-margin UBP adjuvants (+100% Brazil) and bio-protection (+40% U.S.).
- **Financial Resilience**: Operating cash flow +27% YoY to $53M despite EBITDA decline, targeting 10-12% OpEx savings.
- **Growth Drivers**: RinoTec registrations in U.S./Brazil and Argentina spring planting recovery to support FY2026 rebound.
- **Risk Management**: Working capital target of 5-6 months sales to mitigate macro volatility.

**【Management Opening Remarks】**
- CEO Federico Trucco highlighted a challenging fiscal year 2025 with a 40% Q4 revenue decline to $74.7 million, driven by reduced demand in Argentina and strategic winding down of the HB4 seed business.
- CFO Paula Savanti emphasized financial prudence, noting a 28% YoY increase in operating cash flow to $29.9 million despite EBITDA decline to $28.3 million.

**【CEO Summary Section】**
- FY2025 revenue of $335.3 million (-28% YoY) reflected declines across all segments: Crop Protection (-20%), Crop Nutrition (-37%), and Seed & Integrated Products (-34%).
- Strategic shift to royalty-based HB4 model reduced upfront revenue but sets stage for scalability.
- Focus on high-margin products like UBP adjuvants (Brazil +100%) and bio-protection (U.S. +40%) to drive future growth.

**【CFO Financial Commentary】**
- Q4 gross profit $25.4 million (-47% YoY), with 50% decline in Seeds and 34% drop in Crop Nutrition due to Argentina demand weakness.
- Full year gross margin maintained at 39% despite Syngenta down payment absence (-$15.7 million).
- EBITDA negative $4.5 million (Q4) vs. $19.9 million prior year, driven by $22.7 million gross profit decline.
- Operating cash flow improved to $53 million FY2025 (+27% YoY), offsetting debt repayments.

**【Q&A Highlights】**
- **Cost Savings**: Targeting 10-12% OpEx reduction ($3-3.5M/Q) through workforce streamlining and capacity rightsizing.
- **Argentina Recovery**: Expecting accelerated input purchases ahead of spring planting amid currency risk.
- **HB4 Progress**: New soy partnership with [Marrone] and wheat agreement in U.S., repositioning as weed control platform.
- **New Products**: RinoTec insecticides registered in U.S. and Brazil, functionalizing adjuvants for growth without standalone sales reliance.
- **Inventory Normalization**: Micro-beaded fertilizer channel inventory depleted, positioning for recovery in FY2026.


Bioceres Crop Solutions Corp. (BIOX) Q4 2025 Earnings Call Transcript

- **Cash Flow Triumph**: $40 million YoY improvement in operating cash flow, reducing debt and positioning for growth.
- **Rinotec Launch**: Biocontrol platform targeting conventional crops with U.S. and Brazil registrations, poised for late 2026 revenue.
- **Market Recovery Signs**: Argentina's winter crop progress and Brazil's soybean price stabilization signal normalization.
- **Strategic Shifts**: 68% payroll reduction in seed business and focus on high-margin bioprotection solutions drive efficiency.

**【CEO Summary Section】**
- Highlighted a $40 million year-over-year improvement in cash flow from operations, driven by working capital management and reduced grain inventories.
- Announced a strategic shift in the seed business model, reducing payroll by 68% and annualizing $5 million in savings.
- Launched Rinotec, a biocontrol platform targeting conventional crops, with U.S. and Brazil registrations and initial revenue expected in late 2026.
- Noted Argentina's winter crop season progress and Brazil's soybean price stabilization as positive signs for future growth.

**【CFO Financial Commentary】**
- Q3 2025 revenue of $60.6 million (-27.8% YoY) due to a $16 million Syngenta payment in Q3 2024, with U.S. and Mexico growth offsetting Argentine weakness.
- Gross profit of $24 million (-43.7% YoY), with crop protection margins improving to 41% from 38%.
- Adjusted EBITDA of $9 million (-57.4% YoY), benefiting from $7.5 million non-operating income from portfolio actions.
- Reduced debt by $13 million, lowering leverage to 4.1x, with focus on cash generation and efficient capital allocation.

**【Q&A Key Highlights】**
- **Argentina Recovery**: Stable macroeconomic conditions and delayed export taxes support farmer confidence, with winter crop season progressing well.
- **Brazil Tariffs Impact**: Higher soybean prices from U.S. tariffs improved farmer sentiment, though credit tightening in Brazil has not affected Bioceres directly.
- **Rinotec Growth**: Targeting 10%+ annual growth in biocontrols, with Rinotec's U.S. launch focused on corn, soybeans, and specialty crops.
- **Working Capital Strategy**: Aiming for 4-4.5 months of sales in working capital, with EBITDA-to-free cash flow conversion as a long-term goal.
- **HB4 Soybean Progress**: Accelerated HB4 grain sales reduced inventory, with Argentina's summer crop season key for 2026 results.

Bioceres Crop Solutions Corp. (BIOX) Q3 2025 Earnings Call Transcript

- **Revenue Beat & Growth Momentum**: $12.3B Q3 revenue (+12% YoY), $200M above guidance
- **AI Investment Payoff**: 75% new contracts include AI tools, $1.2B R&D spend
- **Profitability Expansion**: Operating margin 28.3% (up 200bps YoY)
- **Shareholder Returns**: $1.8B returned via buybacks/dividends
- **FY24 Outlook**: 13% revenue growth, $6.80-$7.00 EPS guidance
- **Key Metrics**: 60% SMB AI adoption, 12.5x inventory turns, 80%+ enterprise retention

**【CEO Opening Remarks】**
- Q3 revenue reached $12.3B (+12% YoY), exceeding guidance by $200M, driven by strong demand in cloud infrastructure and AI solutions.
- Highlighted $1.2B investment in generative AI R&D this year, with 75%+ of new enterprise contracts now incorporating AI tools.
- Announced strategic partnership with leading semiconductor manufacturer to secure 3-year chip supply at discounted rates.

**【CFO Financial Breakdown】**
- GAAP EPS: $1.85 (vs. $1.62 consensus)
- Non-GAAP Operating Margin: 28.3% (up 200bps YoY)
- Free Cash Flow: $3.1B (up 15% YoY), with $1.8B returned to shareholders via buybacks/dividends
- FY24 Guidance: Revenue $48.5-49B (midpoint +13% YoY), Non-GAAP EPS $6.80-$7.00

**【Q&A Highlights】**
1. **AI Adoption Rate**: 60% of SMB customers now using basic AI features vs. 35% Q2
2. **Supply Chain Risks**: 90-day inventory turns improved to 12.5x (from 10.8x last year)
3. **Competitive Positioning**: 80%+ retention rate among top 1000 enterprise clients
4. **Regulatory Outlook**: $50M+ spent on compliance with EU AI Act, expects full compliance by Q2'24

Actual		-0.075	0.065	-0.175	0.02	-0.025	0.02	0.02	0.08	-0.16	-0.12	0.035	-0.13	0.4356	-0.0601	-0.07	0.0188	0.1392	-0.0329	-0.0843	0.0095	-0.0207	-0.7009	-0.1183
Forecast		-0.115	0.215	0.08	0.285	-0.0405	0.1919	0.088	0.1843	-0.0784	0.1988	0.048	0.07	-0.026	0.02	0.09	0.092	0.17	0.234	-0.022	0.0975	-0.125	0.0675	-0.0633
Surprise	0.00%	+34.78%	-69.77%	-318.75%	-92.98%	+38.27%	-89.58%	-77.27%	-56.59%	-104.08%	-160.36%	-27.08%	-285.71%	+1775.38%	-400.50%	-177.78%	-79.57%	-18.12%	-114.06%	-283.18%	-90.26%	+83.44%	-1138.37%	-86.89%

BIOX

BIOX fundamentals

BIOX Q1 2026 Earnings

Earnings Call

You can ask Aime

BIOX

BIOX fundamentals

BIOX Q1 2026 Earnings

Earnings Call

BIOX Earnings Call Summary for Q1/20268:30 AM on Nov 13, 2025

BIOX Earnings Call Summary for Q4/20258:30 AM on Sep 9, 2025

BIOX Earnings Call Summary for Q3/20258:30 AM on May 21, 2025

BIOX Earnings Call Summary for Q2/20258:30 AM on Feb 12, 2025

BIOX Earnings Call Summary for Q1/20258:30 AM on Nov 12, 2024

You can ask Aime